SURE DENMARK/SWEDEN: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes
Phase of Trial: Phase IV
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SURE DENMARK/SWEDEN
- Sponsors Novo Nordisk
- 20 Dec 2018 Planned End Date changed from 22 Jun 2020 to 18 May 2020.
- 20 Dec 2018 Planned primary completion date changed from 22 Jun 2020 to 18 May 2020.
- 11 Sep 2018 Status changed from not yet recruiting to recruiting.